Investors are optimistic about WW International, formerly known as Weight Watchers, as the market for weight-loss drugs continues to grow.
Analysts are projecting that these drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, will become “megablockbusters,” leading to a surge in WW’s stock price by 59%. Weight Watchers offers personalized diet plans and weight loss coaching through a monthly subscription service, making it well-positioned to benefit from the trend.
The company recently acquired Sequence, a telemedicine service that focuses on weight loss and the prescription of weight-loss medications. This acquisition opens up a new market of potential users, which Goldman Sachs estimates to be around 6 million and could grow to 11 million by 2027.
The acquisition led to a boost in Weight Watchers’ market value of $150 million, and analysts predict that Weight Watcher’s earnings per share could reach $1.69 in 2025, up from a previous projection of $0.48. As a result, Goldman Sachs has raised its recommendation to “buy” and increased its price target from $3.8 to $13. Despite the positive news, WW’s stock closed the day at $6.55.